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A Meta-Analysis of Gene Expression Data Identifies
a Molecular Signature Characteristic for Tumor-Stage
Mycosis Fungoides
Marloes S. van Kester1, Martin K. Borg1, Willem H. Zoutman1, Jacoba J. Out-Luiting1, Patty M. Jansen2,
Enno J. Dreef2, Maarten H. Vermeer1, Remco van Doorn1, Rein Willemze1 and Cornelis P. Tensen1
Mycosis fungoides (MF) is the most common type of primary cutaneous T-cell lymphoma (CTCL). To identify a
molecular signature characteristic of MF tumor stage, we used a bioinformatic approach involving meta-analysis
of publicly available gene expression data sets combined with previously generated gene expression data.
Results for a selection of genes were further refined and validated by quantitative PCR and inclusion of
additional controls. With this approach, we identified a profile specific for MF tumor stage, consisting of 989
aberrantly expressed genes, the majority of which (718 genes) are statistically significantly more expressed in MF
compared with normal skin, inflamed skin, and normal T cells. As expected, the signature contains genes
reflecting the highly proliferative characteristic of this T-cell malignancy, including altered expression of cell
cycle and kinetochore regulators. We uncovered details of the immunophenotype, suggesting that MF
originates from IL-32-producing cells and identified previously unreported therapeutic targets and/or diagnostic
markers, for example, GTSF1 and TRIP13. Loss of expression of the NF-kB inhibitor, NFKBIZ, may partly explain
the enhanced activity of NF-kB, which is a hallmark of MF and other CTCLs.
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INTRODUCTION
Mycosis fungoides (MF) is the most common type of primary
cutaneous T-cell lymphoma (CTCL), consisting of skin-
homing CD45ROþ effector memory T cells. MF patients
present with an evolution of patches, plaques, and tumors.
Stages are related to life expectancy; tumor-stage MF has an
unfavorable prognosis with a 10-year survival of approxi-
mately 40% (van Doorn et al., 2000; Kim et al., 2003).
Although for MF numerous genetic and genomic studies
are described, ranging from investigating individual gene
(mutation)s (Dereure et al., 2002; Scarisbrick et al., 2002) to
genome-wide (array-based) analyses (Karenko et al., 2007;
van Doorn et al., 2009; Laharanne et al., 2010; Salgado et al.,
2010), the molecular (patho) biology of the disease is still
poorly understood.
Reconstruction of (aberrant) gene expression patterns by
comparing gene expression profiles from MF tumor biopsies
(MF-TS) with normal counterparts offers the possibility to
identify pathobiologically relevant genes in MF tumor cells.
However, a genuine comparison of MF tumor cells with
normal (skin-homing) T cells is difficult to achieve, because
skin biopsies of MF contain tumor T cells, but also an admixed
infiltrate of immune cells and resident cells (keratinocytes,
fibroblasts, endothelial cells, etc.). Previous gene expression
studies on MF and other cutaneous lymphoma tried to
circumvent this drawback by either comparing different types
of lymphoma (Dijkman et al., 2007; van Kester et al., 2010),
different stages of the disease (Shin et al., 2007), or analyzing
copy number effect on mRNA expression (van Doorn et al.,
2009). One previous study that directly compared MF
with benign counterparts identified 27 genes implicated in
tumorigenesis, but in this study the expression of only a
limited number of genes was analyzed (Tracey et al., 2003).
In this study, we performed a meta-analysis on raw gene
expression data available in public repositories, selecting
high-quality data sets from normal T-cell (subset)s, skin,
inflamed skin, and MF-Ts, generated with commercially
available Gene chips. Subsequently, these data sets were
corrected for inaccurate gene annotations (Dai et al., 2005).
We took advantage of recent developments in bioinformatics
and subjected the data sets to a robust statistical analysis
comparing expression data of MF tumor samples with normal
T-cell (subset)s and normal skin, as well as inflamed skin from
experimentally induced allergic contact dermatitis simulta-
neously. Finally, we confirmed altered expression of selected
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genes by reverse transcriptase–coupled quantitative (RT–q)
PCR in a series of controls including benign T-cell dermatoses
and early-stage MF. Using this approach, we identified a gene
expression pattern characteristic for MF tumor stage, provid-
ing more insight into the pathogenesis of this lymphoma,
a description of its (immuno) phenotype, and the discovery
of previously unreported putative diagnostic markers and
therapeutic targets.
RESULTS
In silico analysis: identification of differentially expressed genes
Screening and filtering strategy for the identification of MF
tumor-specific genes. To identify MF tumor genes, we
designed a strategy (the workflow is shown in Figure 1a)
eventually generating a list of differentially expressed (DE)
genes characteristic for MF tumor stage. First, gene expres-
sion data sets were obtained by searching for Affymetrix
U133 plus 2.0 Gene chip (designated as GPL570 in the
Gene Expression Omnibus, GEO) in combination with
the keywords skin and/or (activated) T cells and/or T-cell
lymphoma, revealing approximately 15 suitable hits. Down-
loaded CEL files and previously generated expression profiles
(e.g., 22 MF-Ts; van Doorn et al., 2009) were subjected
to the Affymetrix QC metrics and individual samples passing
the control (Table 1 and Supplementary Table S1 online)
were included for further analyses. Next, we compared gene
expression profiles of MF-Ts one to one with skin or
(reference) T cells. Not surprisingly, comparing MF tumor
samples with skin (or inflamed skin only) revealed a large
number of typical T-cell (related) genes, whereas comparison
between MF-T biopsies and T cells produced a long list of DE
genes indicative for skin (results not shown). To identify genes
that are specifically enriched or depleted in MF-T (‘‘unique
genes’’), we decided to perform a comparison between the
lists of DE genes, identified by the pairwise comparisons,
using an ‘‘AND’’ operator (Watkins et al., 2009) and to
look for genes that were consistently upregulated or down-
regulated. To that end, the MF-T samples (n¼20) were
compared with the Pedersen data of skin (clinically normal
skin, n¼ 16) AND inflamed skin (n¼9) AND all reference
T cells (n¼42). Because of the limited group sizes, we
restricted the number of false positives by applying multiple
testing correction (Benjamini–Hochberg) at stringent settings
(false discovery rate o0.01).
This overlap analysis resulted in a list of 989 genes, of
which 271 were downregulated and 718 were overexpressed
in MF-Ts. The top lists are given in Table 2a and b, whereas
a full searchable table is available in the Supple-
mentary Information Table S2 online. This list was used for
the detailed analysis described below. To further validate our
approach, we also carried out a similar comparison for MF-T,
T cells, and the data set from Yao et al. (2008), containing
normal skin, uninvolved skin, and lesional skin from psoriasis
patients. This analysis showed that the majority of genes
(but not all) found to be characteristic for MF-T are also
consistently and DE compared with these data sets (596 up
and 195 down; results are provided in Supplementary
Information Table S3 online).
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Figure 1. Strategy and results of the in silico identification of the molecular
signature of mycosis fungoides (MF) tumor stage. (a) Workflow (1) data sets
were obtained by searching for Affymetrix U133 versus 2 Gene chip
(GPL570). (2) The quality of the data sets was checked using a series of QC
metrics. (3) Gene expression data were reannotated according to the Entrez
genome annotation using CDF files. (4) GC-RMA (robust multiarray
averaging) normalization was applied. (5) Differentially expressed (DE) genes
were identified with LIMMA using a log 2 fold change X1 as a threshold, an
adjusted P-value of o0.01, and the ‘‘AND’’ operator to identify consistently
upregulated or downregulated genes. (6) Analysis of DE genes. (7) Quantitative
PCR (qPCR) was used to validate differential expression in additional samples.
(b) Venn diagram illustrating the number of genes that show altered
expression in MF tumor stage compared with normal skin (NS), inflamed skin
(IS), and T cells. Values indicate the number of genes significantly (left)
upregulated or (right) downregulated. The intersecting regions represent
number of genes that are common to the specific comparisons.
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Systematic and integrative analysis of DE genes
Gene-annotation enrichment analysis. Next, Internet-based
gene-annotation category enrichment analysis programs (PPI
spider, DAVID, Panther, Webgestalt; Thomas et al., 2003;
Zhang et al., 2005; Antonov et al., 2009; Huang et al., 2009a, b)
were applied to gain further insight into the (clinical)
relevance of the MF DE genes and all gave similar results.
For example, using PPI spider classification (Supplementary
Table S4a–c online), we observed that genes associated
with ‘‘mitosis’’, ‘‘cell division’’, ‘‘cell cycle’’, ‘‘spindle’’, and
‘‘spindle organization’’ are over-represented in the list of
DE MF genes, which is in line with the malignant
(proliferative) phenotype of tumor-stage MF. The enrichment
for genes involved in ‘‘immune response’’ is consistent with
the T-cell origin of MF. Closer inspection of the ‘‘immunity
genes’’ in Supplementary Table S4 online revealed over-
expression of several IFN-responsive genes (IFI27, IFI6, IFI30,
IFI35), interleukin/chemokines genes (IL10, IL15, IL26, IL32,
CCL18, CXCL9, -10, -11, and -13) and receptors (IL13RA2,
IL15RA, CCR1, -8, and -10), and downregulation of IL11RA.
Functional annotation analysis of downregulated genes
identified a single category: RNA processing (Supplementary
Table S4c online).
Comparison of molecular signatures. Comparison of the
‘‘MF-T signature’’ with the most recent Cancer Gene census
list (updated 15 November 2011; first described by Futreal
et al. (2004)) identified 32 bona fide cancer genes (see
Supplementary Table S5 online). We also determined
whether differential expression of genes could be related to
known genomic alterations. However, none of the ‘‘top 30’’
DE genes (Table 2a and b) resides within previously
described minimal common regions of genetic imbalances
(van Doorn et al., 2009).
Promoter hypermethylation
We investigated the promoter sites of downregulated genes
for CpG islands using the UCSC genome browser (http://
genome.ucsc.edu/) and found CpG islands present in the
promoter start sites in more than 70% of the downregulated
genes, suggesting a possible role of promoter hypermethyl-
ation. Subsequently, bisulfite conversion followed by PCR
and melt-curve analysis was used to test CpG islands for
methylation (Worm et al., 2001; Senff et al., 2009). Bisulfite-
treated DNA isolated from tumor biopsies of MF patients
(n¼22) and CD4þ T-cell controls (n¼6) were used as
input, and CpG islands in the promoter regions of NFKBIZ,
ATXN7, and MXI1 were amplified. Primers were developed
in such a way that both methylated and unmethylated
sequences are amplified using the same bisulfite-treated DNA
as PCR template. In none of the resulting melting-curve
analyses of PCR products (see Supplementary Figure S1
online) could methylation be demonstrated, although all
contained PCR products representing unmethylated DNA.
We therefore concluded that promoter hypermethylation
does not have a role in the downregulation of these genes in
MF tumor stage.
Verification of MF DE genes using qPCR
Differential expression for a selection of genes (as material is
limited) was verified using RT–qPCR (results summarized in
Figure 2; P-values from statistical evaluation (Mann–Whitney)
can be found in Supplementary Table S6 online). We
included mRNA isolated from skin biopsies of patients with
chronic discoid lupus erythematosus, early-stage MF (IA/B),
chronic eczematous dermatitis (CED), normal skin, and
freshly isolated CD4þ T cells of healthy donors as additional
samples. Instead of solely confirming the highest differences,
we focused on genes that represent different classes, which
Table 1. Samples included in the comparative analyses
Group Subtype Reference No. of samples (passing QC)
MF MF tumor skin biopsy van Doorn et al. (2009) 20
Normal T cells CD3+ T cells Mosig et al.* 12
CD4+ T cells Piccaluga et al.* 2
CD8+ T cells Piccaluga et al.* 4
Resting CD3+ T cells Piccaluga et al.* 5
Activated CD3+ T cells Piccaluga et al.* 5
CD4+ T cells Ledieu et al.* 7
CD8+ T cells Ledieu et al.* 7
Skin Control skin biopsiesþACD with no clinical signs Pedersen et al. (2007) 16
Inflamed skin ACD skin biopsy (clinical signs) Pedersen et al. (2007) 9
Skin Normal skin biopsy Yao et al. (2008) 17
Psoriasis Uninvolved skin psoriasis biopsy Yao et al. (2008) 27
Psoriasis Lesional skin psoriasis biopsy Yao et al. (2008) 31
Abbreviations: ACD, allergic contact dermatitis; MF, mycosis fungoides; QC, quality control.
*Database numbers for these (and other) studies are provided in Supplementary Table S1 online.
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Table 2. Top lists (30) of genes differentially expressed in MF versus NS and IS and T cells: ranked on (a) log fold
change MF versus IS (in bold) and (b) log fold change MF versus T cells (in bold)
Down in MF Log 2 fold change Up in MF Log2 fold change
HGNC
symbol
Entrez
ID
MF
versus NS
MF
versus IS
MF versus
T cell
HGNC
symbol
Entrez
ID
MF
versus NS
MF
versus IS
MF versus
T cell
(a)
TAOK1 57551 5.30 5.20 4.26 ADAMDEC1 27299 6.93 7.20 6.72
PSAPL1 768239 4.56 4.77 1.00 IL32 9235 7.97 7.12 3.20
NR1D2 9975 5.31 4.55 5.46 GTSF1 121355 6.64 6.65 4.98
ZBTB20 26137 4.72 4.25 3.66 CXCL13 10563 6.44 6.50 4.58
ATXN7 6314 3.24 4.13 5.45 RRM2 6241 6.92 6.21 4.95
UGCG 7357 3.70 3.82 3.28 PTPRCAP 5790 6.86 6.04 1.09
EPHA4 2043 3.68 3.68 2.66 CXCL9 4283 5.83 5.81 8.22
KIAA0754 643314 2.99 3.65 3.02 SPP1 6696 5.81 5.69 6.22
SLC16A7 9194 3.26 3.61 3.07 PTPN7 5778 6.61 5.43 1.15
MAST4 375449 2.98 3.59 1.83 DLGAP5 9787 4.72 5.30 4.95
ABCA5 23461 4.05 3.50 3.06 UBD 10537 5.77 5.22 7.99
ZBTB16 7704 3.64 3.47 1.95 CKS2 1164 4.08 5.15 3.33
NKTR 4820 3.26 3.46 3.86 CCL18 6362 7.36 5.04 8.57
NFKBIZ 64332 2.75 3.42 4.07 MMP1 4312 5.79 4.81 5.74
RPS27P19 100129905 2.62 3.39 5.51 CEP55 55165 4.73 4.77 4.52
DICER1 23405 3.42 3.36 3.25 TMEM163 81615 4.68 4.68 4.17
ZBTB43 23099 2.77 3.26 2.70 UBE2C 11065 4.96 4.66 5.79
MALAT1 378938 2.48 3.26 2.75 IDO1 3620 4.17 4.57 3.99
IL6ST 3572 3.18 3.22 2.64 HMMR 3161 4.17 4.55 4.27
ATP7A 538 3.81 3.17 2.63 MAD2L1 4085 4.21 4.54 2.53
EIF2C2 27161 2.83 3.16 3.82 PLA2G2D 26279 4.54 4.54 4.50
NSUN6 221078 2.83 3.12 3.53 IQCG 84223 4.74 4.45 4.44
PLEKHA1 59338 3.37 3.11 2.10 AURKB 9212 4.49 4.41 4.36
EIF2C3 192669 2.78 3.03 2.74 TRIP13 9319 4.84 4.39 4.75
TCF7L2 6934 3.93 2.94 1.35 ASF1B 55723 4.58 4.38 4.16
GSK3B 2932 2.36 2.92 1.61 CDC20 991 4.56 4.38 5.20
DKFZP586I1420 222161 2.57 2.92 2.71 CCNA2 890 4.50 4.37 4.34
PIK3R1 5295 3.27 2.91 3.46 CXCL10 3627 4.95 4.31 6.79
C2orf40 84417 3.79 2.91 1.34 CENPA 1058 3.97 4.30 4.22
LOC654340 654340 2.70 2.89 2.89 APOBEC3B 9582 3.87 4.27 3.59
(b)
FGFBP2 83888 3.62 2.45 5.93 CCL18 6362 7.36 5.04 8.57
RPS27P19 100129905 2.62 3.39 5.51 KRT6C 286887 3.92 4.19 8.46
NR1D2 9975 5.31 4.55 5.46 IFI27 3429 1.66 1.19 8.28
ATXN7 6314 3.24 4.13 5.45 CXCL9 4283 5.83 5.81 8.22
TAOK1 57551 5.30 5.20 4.26 UBD 10537 5.77 5.22 7.99
NFKBIZ 64332 2.75 3.42 4.07 C1QC 714 2.70 2.61 7.59
GPRASP1 9737 2.87 1.76 4.06 C1QA 712 2.54 2.91 7.54
LOC100132279 100132279 1.61 1.50 4.00 C1QB 713 3.15 3.41 7.17
Table 2 continued on the following page
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might give further insights into the disease and/or previously
unreported putative targets for diagnosis/therapy. We noticed
that the array comparison indicated dysregulation of multiple
genes involved in the microRNA (miRNA) biogenesis/
machinery, and aberrant expression of proteins involved in
miRNA processing has been observed in T-cell lymphoma
including Se´zary syndrome (Lawrie et al., 2009). We there-
fore also included RNASEN, DICER, EIF2C1, EIF2C2, EIF2C3,
and EIF2C4 in the RT–qPCR validation. GeNorm analysis
(Vandesompele et al., 2002) revealed that EIF2C4 was stably
expressed in all samples, and therefore in addition to ARF5,
TMEM87a and ERCC3 (see Materials and Methods) was used
as a reference gene. Initial experiments could not detect any
significant differences in DICER and EIF2C3 expression
between samples and controls; therefore, these genes were
excluded from subsequent analysis.
With RT-qPCR down-regulation of ATXN7, ZBTB20,
NFKBIZ, in MF-T in comparison to CD4þ T-cells and normal
skin could be affirmed. ZBTB20 was also significantly less
expressed in MF-T compared with CLE and early-stage MF,
whereas NFKBIZ is lower in MF-T compared with all
controls. Expression of ATXN7, however, was higher in
MF-T versus CED and early-stage MF.
We observed that the expression of RNASEN and
EIF2C1 in MF-T is not different from control CD4þ T cells;
however, the expression of RNASEN is higher in MF-T
compared with early-stage MF and CED, whereas that of
EIF2C1 is lower in MF-T compared with CLE. EIF2C2
expression in MF-T was lower in CD4þ T cells and CED,
but not different from early-stage MF, CED, and normal skin.
With RT–qPCR, the overexpression of CXCL13, TRIP13,
GSTF1, and IL32 in MF-T compared with freshly isolated
CD4þ T cells and normal skin was confirmed (Figure 2).
CXCL13, a marker for follicular helper T cells, showed
variable expression among all biopsies, but is overexpressed
in MF-T versus early-stage MF. TRIP13, a gene encoding a
key protein for chromosome development, is highly up-
regulated in MF-T versus control biopsies, whereas IL32,
a gene belonging to the immune cluster, and the gene
encoding the gametocyte-specific protein, GTSF1 (gameto-
cyte specific factor 1), are nearly exclusively expressed in
MF-T patients.
Table 2. Continued
Down in MF Log 2 fold change Up in MF Log2 fold change
HGNC
symbol
Entrez
ID
MF
versus NS
MF
versus IS
MF versus
T cell
HGNC
symbol
Entrez
ID
MF
versus NS
MF
versus IS
MF versus
T cell
NKTR 4820 3.26 3.46 3.86 CXCL10 3627 4.95 4.31 6.79
EIF2C2 27161 2.83 3.16 3.82 ADAMDEC1 27299 6.93 7.20 6.72
ZNF331 55422 1.38 1.36 3.82 APOE 348 1.01 1.00 6.64
UHMK1 127933 2.32 2.42 3.76 VCAM1 7412 2.88 2.40 6.23
ZBTB20 26137 4.72 4.25 3.66 SPP1 6696 5.81 5.69 6.22
RASA2 5922 1.28 1.50 3.61 UBE2C 11065 4.96 4.66 5.79
BEX2 84707 1.70 1.07 3.57 TMEM176B 28959 2.62 2.94 5.77
NSUN6 221078 2.83 3.12 3.53 MMP1 4312 5.79 4.81 5.74
ZNF44 51710 1.78 1.99 3.52 CTSZ 1522 4.59 4.18 5.22
PIK3R1 5295 3.27 2.91 3.46 CDC20 991 4.56 4.38 5.20
NLRP1 22861 1.19 1.53 3.45 MMP9 4318 5.29 3.74 5.11
C2orf82 389084 1.82 1.32 3.44 GTSF1 121355 6.64 6.65 4.98
ADRB2 154 2.84 2.50 3.36 CDC2 983 3.88 4.08 4.95
NR3C2 4306 3.65 2.61 3.35 DLGAP5 9787 4.72 5.30 4.95
UGCG 7357 3.70 3.82 3.28 RRM2 6241 6.92 6.21 4.95
FLJ10213 55096 1.80 2.37 3.27 TOP2A 7153 3.61 3.94 4.84
DICER1 23405 3.42 3.36 3.25 TYMP 1890 4.84 3.01 4.79
C5orf41 153222 2.24 1.37 3.22 TRIP13 9319 4.84 4.39 4.75
LOC731484 731484 1.44 1.21 3.20 MS4A4A 51338 1.60 2.37 4.67
ZCCHC2 54877 1.96 2.23 3.13 BUB1B 701 3.68 3.96 4.61
LCOR 84458 1.97 1.91 3.11 TYMS 7298 4.48 3.98 4.61
SLC16A7 9194 3.26 3.61 3.07 SLAMF8 56833 3.78 3.12 4.60
Abbreviations: HGNC, HUGO Gene Nomenclature Committee; IS, inflamed skin; MF, mycosis fungoides; NS, normal skin.
Left, downregulated genes; right, upregulated genes.
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DISCUSSION
The purpose of this study was to distill the gene expression
profile of MF tumor stage, aiming to gain more insight into
the pathogenesis and the molecular basis of this disease. We
performed a meta-analysis using high-quality data sets
generated with commercially available Gene chips, a robust
Summary of statistical evaluation
MF-T versus MF IA/B CED CDLE CD4+ T cells Normal skin
Genes
ATXN7 UP ** UP *** NC DOWN *** DOWN **
ZBTB20 DOWN *** NC DOWN *** DOWN *** DOWN ***
NFKBIZ DOWN * DOWN ** DOWN * DOWN *** DOWN **
RNASEN UP * UP *** NC NC NC
EIF2C1 NC UP * DOWN * NC NC
EIF2C2 NC DOWN * NC DOWN *** NC
CXCL13 UP * NC NC NA NA
TRIP13 UP *** UP *** UP ** UP *** UP ***
GTSF1 UP ** NA UP *** UP ** UP ***
IL32 UP *** UP ** UP *** UP ** UP ***
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Figure 2. Relative mRNA expression levels for a selection of genes in normal skin (NS), CD4þ T cells, cutaneous discoid lupus erythematosus (CDLE),
chronic eczematous dermatitis (CED), early-stage mycosis fungoides (MF, IA/B), MF tumor (MF, T) samples, and the cell line MyLa. The mRNA expression
levels were measured by reverse transcriptase–coupled quantitative PCR (RT–qPCR) and calculated relative to ARF5, EIF2C4, TMEM87a, and ERCC3, used
as a reference gene set and depicted for individual samples as dots. The median and interquartile range for each sample and gene under study are given.
Summary of statistical evaluation (Mann–Whitney U-test) denotes relative expression of gene in MF tumor versus sample group. P-values: *o0.05, **o0.01,
and ***o0.001; complete data are provided in Supplementary Table S6 online. NC¼no change; NA¼Mann–Whitney not applicable as the gene is not
expressed in this group, resulting in ex aequo values.
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statistical analysis, and compared/studied expression data of
MF tumor stage with normal T-cell (subset)s, normal skin, and
inflamed skin (from experimentally induced allergic contact
dermatitis or psoriasis). With this approach, we identified 989
genes significantly DE in MF-T, the majority of which (718)
are more expressed and 271 genes are less expressed in MF
tumor stage. After submitting the extracted gene lists to
Internet-based gene set enrichment tools, various classes of
genes could be distinguished. The most apparent classes
contained genes that can be considered as ‘‘usual suspects’’,
being hallmarks of proliferating cells such as genes involved
in mitosis, cell division, cell cycle, including kinetochore
formation, and DNA replication. From these clusters, several
genes and corresponding proteins were previously described
in MF, e.g., the overexpression of MCM7 protein, a member
of the minichromosome maintenance complex, in tumor-
stage MF (Gambichler et al., 2008). Our results, however,
suggest that not only MCM7 but also MCM2–6, ORCL1,
CDC6, and CDC7 belonging to the MCM7 complex are
upregulated. These results are in line with the notion that
(collective) upregulation of kinetochore and proliferation
genes can lead to aberrant chromosome separation, and
hence contribute to genomic instability in tumors including
lymphoma (Sanchez-Aguilera et al., 2006). On the basis
of our results, especially the high expression of UBE2C, one
of the key regulators of cell cycle completion and marker of
grade of malignancy in lymphoma (Troncone et al., 2009),
might have a central role in chromosomal instability as
observed in MF (van Doorn et al., 2009; Salgado et al., 2010).
In analogy, the overexpression of TRIP13 in MF-T (confirmed
by RT–qPCR) is of interest. TRIP13 has a prominent role in
chromosome recombination and chromosome structure
development, and mRNA overexpression was recently cor-
related with prostate cancer progression (Larkin et al., 2011).
We noticed that a large proportion of downregulated
genes in tumor MF contained CpG islands in their promoter
region. As DNA methylation of tumor suppressor genes has
been found in MF (van Doorn et al., 2005), we screened
several of these genes for DNA promoter hypermethylation.
For none of the genes tested, however, could promoter
DNA hypermethylation be confirmed, indicating that other
mechanisms are responsible for downregulation of these
genes (e.g. aberrant expressed transcription factors or
miRNA-induced mRNA degradation; Croce, 2009). Among
the downregulated genes, in comparison with healthy
CD4þ T cells and benign dermatoses, we also detected
(and confirmed by PCR) decreased expression of Argonaute 2
(EIF2C2), a protein belonging to the RNA-induced silencing
complex and an essential component of the miRNA
machinery (Esquela-Kerscher and Slack, 2006). As aberrant
expression of other proteins involved in miRNA processing
has been observed in T-cell lymphoma, including Se´zary
syndrome (Lawrie et al., 2009), we also determined the
expression of Argonaute 1, 3, and 4 (encoded by EIF2C1,
EIF2C3, and EIF2C4), DICER, and Drosha (RNASEN) using
RT–qPCR. We could only demonstrate upregulation of
RNASEN in MF tumor stage compared with early-stage MF
and downregulation of EIF2C1 in MF-T in comparison with
chronic discoid lupus erythematosus. When comparing the
MF tumor ‘‘signature’’ with signatures for CTCL (Shin et al.,
2007; Litvinov et al., 2010), we identified nine genes in the
so-called ‘‘cluster 1’’ that are shared with our study: IL26,
PTPN7, TNFSF14, TNFSF4, CCR8, FUT7, CXCL13, LILRB4,
and ST8SIA4 (all upregulated in cluster 1). Comparison of the
MF tumor DE genes with the Cancer Gene census database
(Futreal et al., 2004) revealed differential expression of 32
bona fide cancer genes in tumor-stage MF.
Immunophenotype
Our results show upregulation of both IFN-responsive genes
(e.g. STAT1; Fantin et al., 2008) and several interleukin/
chemokines genes previously demonstrated to be upregu-
lated in MF tumor cells (IL10 (Asadullah et al., 1996), IL15
(Asadullah et al., 2000)), or surrounding cells (CXCL9, 10 in
keratinocytes (Tensen et al., 1998); CCL18 in macrophages
(Gunther et al., 2011)). Our analysis could not confirm
elevated expression of CCL17 (Kakinuma et al., 2003). With
regard to the cytokine receptors, high expression of IL15RA is
in line with the reported sensitivity of MF cells for IL15
(Dobbeling et al., 1998), whereas expression of IL13RA2
is not yet described for (cutaneous) lymphoma. We noticed
increased expression of the chemokine receptors CCR1,
CCR8, and the skin-homing receptor CCR10. A role for CCR8
in localization of cutaneous memory T cells to the skin was
proposed earlier (Colantonio et al., 2002), although no data
on CCR8 (protein) expression in MF are available as yet. In
contrast to FACS-based data of Campbell et al. (2010) and
Clark et al. (2011), our gene expression data do not show
upregulation of CCR4 in MF-T. This might be explained by a
high variable expression in either group (T-MF or controls),
and consequently do not reach statistical significance. The
gene expression data provide some evidence for the
suggestion that MF is derived from Th17 cells (Ciree et al.,
2004): increased IL-26 mRNA levels even though increased
expression of IL-17 is not detected, whereas genesis from
Th22 (no increase in IL-22), Treg (no FoxP3 overexpres-
sion), or T follicular helper cells (no upregulation of ICOS
or programmed cell death 1) is unlikely. Instead, we
observed a large degree of heterogeneity in the expression
of another putative T-follicular helper marker, CXCL13, as
well as increased expression of programmed cell death 1
ligand 2.
We did find high and consistent expression of IL-32 mRNA
in all patients, which was confirmed by RT–qPCR data
showing expression of IL-32 in MF-T and MyLa, but not in
early-stage MF, benign controls, and normal skin. Although
these findings suggest that MF might originate from ‘‘Th32’’
cells, it remains to be proven that the tumor T cell is the
source of IL-32, especially as recent studies described IL-32
production by fibroblasts (in rheumatoid synovium; Alsaleh
et al., 2010), keratinocytes (Meyer et al., 2010), and mast
cells (Kempuraj et al., 2010).
Therapeutic targets and diagnostic markers
Our data are in full agreement with the previously described
aberrant expression of B-lymphoid kinase (BLK) in MF, which
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enhances proliferation induced by constitutive activation of
NF-kB (Krejsgaard et al., 2009) and the described over-
expression of Polo-like kinase 1 (PLK1; Nihal et al., 2011).
Here we also demonstrate that NFKBIZ, a gene encoding an
NF-kB signaling inhibitor, is downregulated in MF (supported
by RT–qPCR data), which might be an explanation for
enhanced NF-kB activity, a hallmark of MF (Izban et al.,
2000). In this respect, targeting of RMM2 (among the DE
genes upregulated in MF-T), which induces NF-kB-depen-
dent MMP9 activation (upregulated in MF-T and in agree-
ment with published protein data; Rasheed et al., 2010)
and thereby enhances cellular invasiveness (Duxbury and
Whang, 2007), warrants further studies; several potent
inhibitors for RRM2 protein were recently described that
cause growth suppression of tumors (Davis et al., 2010).
CD74 overexpression could be targeted by milatuzumab, a
humanized antibody currently tested on lymphoma and
multiple myeloma patients in phase I trials (Mark et al.,
2009). Neither CD52 nor NOTCH-1 or -3 overexpression
could be reproduced in our analysis. CD52 is a target of
alemtuzumab (also known as Campath), and although
previously described as being upregulated at the mRNA
level in CTCL (Hahtola et al., 2006) its use in the treat-
ment of MF and Se´zary syndrome is with varying results
(Gribben and Hallek, 2009). NOTCH-1 is overexpressed
at the protein level in advanced MF (Kamstrup et al., 2010),
but data on mRNA expression are solely obtained from
CTCL cell lines. Overexpression of TOP2A, also identified
in nodal peripheral T-cell lymphoma (Cuadros et al.,
2007), might serve as a target of anthracyclines, such as
doxorubicin and etoposide. We observed that indoleamine
2,3-dioxygenase 2, IDO2, playing a role in immuno-
modulation and tumor escape, is overexpressed in MF tumor
stage. A recent study demonstrated that the small-molecule
inhibitor INCB024360 is able to inhibit IDO2 protein and
can act as an effective immunotherapeutic agent (Liu et al.,
2010).
Finally, we identified a limited number of genes for which
expression appears to be restricted to MF tumor stage and
which might also serve as diagnostic (bio)markers. Among
these is GTSF1. Expression thus far is only described for
gametocytes (Yoshimura et al., 2007), and according to our
mRNA expression analysis (RT–qPCR) is limited to MF tumor
samples. As male GTSF1 knockout mice are sterile, owing to
massive apoptotic death of their germ cells, aberrant (over)-
expression of GTSF1might have a role in apoptosis resistance
in MF.
In summary, we determined a molecular signature
characteristic for MF tumor stage, offering more insight into
the pathogenesis of this disease. Moreover, we uncovered
more details of its immunophenotype: overexpression of
IFN-responsive genes (IFI27, IFI6, IFI30, IFI35), interleukin/
chemokine genes (IL10, IL15, IL26, IL32, CCL18, CXCL9,
-10, -11, and -13) and receptors (IL13RA2, IL15RA, CCR1, -8,
and -10), and downregulation of IL11RA. Finally, our data
suggest previously unreported therapeutic targets and/or
diagnostic markers: IDO2, RRM2, CD74, TOP2A, GTSF1,
TRIP13, and NFKBIZ, which warrant further research.
MATERIALS AND METHODS
In silico analysis
We designed a strategy to identify the molecular signature of MF
tumor stage (the workflow is shown in Figure 1). All data analyses
were performed in R using packages present in Bioconductor
(www.bioconductor.org). The Gene expression omnibus (http://
www.ncbi.nlm.nih.gov/geo/) and ArrayExpress (http://www.ebi.
ac.uk/microarray-as/ae/) databases were screened for data sets,
generated with Affymetrix U133 versus 2 Gene chips (GPL570) in
combination with keywords skin and/or (activated) T cells or T-cell
lymphoma, allowing comparison with gene expression profiles of
MF-Ts generated previously (van Doorn et al., 2009). In addition,
gene expression data of two additional MF-Ts from our lab (both
processed in parallel with previous MF samples) and the CTCL cell
lines Seax, HuT-78, and MyLa (all cultured under standard
conditions) were included in the analysis.
The quality of all data sets was checked using a series of QC
metrics recommended by Affymetrix (using the R-script described by
Heber and Sick (2006)) in order to confirm that arrays were
hybridized correctly, that sample quality was acceptable, and that
batches of data sets could reliably be compared in a meta-analysis.
Data sets in which more than 30% of the individual samples
required exclusion solely based on RNA quality were discarded
entirely. Next, raw gene expression data from Affymetrix CEL files
passing all QC controls were reannotated according to the Entrez
genome annotation using CDF files (Dai et al., 2005), followed
by GC-RMA (robust multiarray averaging) normalization. Samples
passing QC, which were included in the final normalization, are
summarized in Supplementary Table S1 online. For subsequent
analysis, all T-cell expression data from healthy volunteers were
grouped to create a reference of normal T cells. Gene expression
profiles of skin biopsies were clustered and labeled according to
the Supplementary Information given in GEO or ArrayExpress or
accompanying papers (Pedersen et al., 2007; Yao et al., 2008)
(Table 1), resulting in groups labeled as normal skin or inflamed skin
(Pedersen data), or normal skin, uninvolved skin psoriasis, and
lesional skin psoriasis (Yao data). DE genes between groups and MF
tumor stage were identified with LIMMA (Smyth et al., 2005) using a
log 2 fold change X1 as threshold and were considered statistically
significant at an adjusted P-value of o0.01 (using Benjamini–Hoch-
berg multiple testing correction). Subsequently, the ‘‘AND’’ operator
(Watkins et al., 2009) was used to perform a comparison between
the lists of DE genes from the individual comparisons to identify
consistently upregulated or downregulated transcripts in MF. This
comparison resulted in a list of genes enriched or depleted in
MF. Gene enrichment analyses of DE genes were performed with
PPI spider, DAVID, Panther, and Webgestalt (Thomas et al., 2003;
Zhang et al., 2005; Antonov et al., 2009; Huang et al., 2009a, b).
Reverse transcription–coupled qPCR
Array results were validated by RT–qPCR on RNA isolated from fresh
frozen skin biopsies of 21 MF tumors, 6 chronic discoid lupus
erythematosus lesions, 8 early-stage MF (IA/B) patients, 4 patients
with CED, normal skin (n¼ 6), freshly isolated CD4þ T cells of
6 healthy donors as described previously (van Doorn et al., 2004),
and MyLa cells. cDNA was synthesized from 1mg total RNA, after
treatment with RQ1 DNase I (Promega, Madison, WI), using IScript
reverse transcriptase (Bio-Rad, Veenendaal, The Netherlands),
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oligo(dT)12–18, and random hexamer priming (Bio-Rad) in a final
volume of 20 ml. Quantitative real-time PCR (qPCR) was performed
with the MyIQ Detection System and the SYBR Green Supermix
(Bio-Rad).
Primers were intron-spanning designed with Primer3 (http://
frodo.wi.mit.edu/primer3/), and tested in silico with Beacon
Designer (Premier Biosoft, Palo Alto, CA). Before use, all primers
were tested experimentally, assessing the slope, efficiency, and R2
value of dilution series using cDNA synthesized from human
reference RNA (Stratagene Europe, Amsterdam, The Netherlands)
as a template. Primer sequences are listed in Supplementary Table
S5 online. The reference gene set was identified by testing several
optimized primers on all samples included in the validation
experiment and using GeNorm as described earlier (Vandesompele
et al., 2002). The set of ARF5, EIF2C4, TMEM87a, and ERCC3 was
identified as the best option and further used as the reference gene
set. The cycle parameters for transcripts of interest and for the
reference genes used for normalization were as follows: denaturing
for 15 seconds at 97 1C, and annealing and extension for 20 seconds
at 60 1C, for 40 cycles. The nonparametric Mann–Whitney U-test
(one-tailed; Graphpad Prism 5; GraphPad Software, La Jolla, CA)
was used for statistical evaluation of the RT–qPCR results.
Methylation-specific Melting-Curve Analysis PCR
For the bisulfite conversion by the EZ DNA methylation kit (Zymo
Research, Orange, CA), 1 mg genomic DNA (isolated from MF-T skin
biopsies; van Doorn et al, 2009) was used. Primers (Supplementary
Table S5 online) were designed to anneal to the bisulfite-sensitive,
unmethylated strand and the bisulfite-resistant, methylated strand.
Under these conditions, both methylated and non-methylated DNA
will be amplified. Methylation-specific melting-curve analysis PCR
reactions were performed as described earlier (Worm et al., 2001)
with the MyIQ Detection System and the SYBR Green Supermix
(Bio-Rad) in a 25ml reaction volume. Cycle parameters for all
analyzed CpG islands were as follows: denaturing at 96 1C for
30 seconds, annealing at temperatures varying from 65 to 58 1C
depending on the primer set used for 40 seconds, and extension at
72 1C for 40 seconds for eight cycles, followed by denaturing for
30 seconds, annealing at 60 1C for 40 seconds, and extension at
72 1C for 40 seconds for 35 cycles. DNA melting curves were
acquired directly after amplification by measuring the fluorescence
of SYBR Green Supermix (Bio-Rad) during a linear temperature
transition from 65 to 94.8 1C at 0.2 1C s1.
Sensitivity and specificity of the methylation-specific melting-
curve analysis was validated for all primer sets using (mixtures of)
methylated human DNA (Chemicon, Hampshire, UK) or unmethy-
lated human semen DNA as input.
Approval for these studies was obtained from the institutional
review board of the Leiden University Medical Center. Informed
consent was provided according to the Declaration of Helsinki
Principles.
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